Jeffrey M Myers

US Patent:

20070232668, Oct 4, 2007

Filed:

Apr 2, 2007

Appl. No.:

11/695547

Inventors:

Waldemar Priebe - Houston TX, US
Izabela Fokt - Houston TX, US
Slawomir Szymanski - Houston TX, US
Timothy Madden - Sugar Land TX, US
Jeffrey Myers - Bellaire TX, US
Charles Conrad - Spring TX, US

International Classification:

A61K 31/44
C07D 213/57
A61K 31/277
C07C 255/32

US Classification:

514357000, 514521000, 514543000, 514620000, 546330000, 558410000

Abstract:

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

US Patent:

20090170768, Jul 2, 2009

Filed:

Oct 3, 2008

Appl. No.:

12/245438

Inventors:

James M. Tour - Bellaire TX, US
Valerie C. Moore - Houston TX, US
Jeffrey N. Myers - Bellaire TX, US
Zvonimir L. Milas - Houston TX, US
Kathy A. Mason - Houston TX, US
Luka Milas - Houston TX, US
Brandl Katherine Price - Houston TX, US
Jared L. Hudson - Hamilton VA, US
Ashley Leonard - Houston TX, US
Dmitry V. Kosynkin - Houston TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 38/18
A61K 31/337
A61K 47/04

US Classification:

514 12, 514449, 514769, 977746, 977750, 977906

Abstract:

Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are insoluble in water. Methods are described for making the compositions and administering the compositions. An extended release formulation for paclitaxel utilizing functionalized carbon nanotubes is also described.

US Patent:

20100290997, Nov 18, 2010

Filed:

May 11, 2007

Appl. No.:

12/227185

Inventors:

Chun Li - Missouri City TX, US
Wei Wang - Sugar Land TX, US
Marites P. Melancon - Houston TX, US
Juri G. Gelovani - Houston TX, US
Jeffrey Myers - Houston TX, US

International Classification:

A61K 49/06
C07D 403/10
C12Q 1/02
A61K 49/00

US Classification:

424 93, 548455, 435 29, 424 91

Abstract:

The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional contrast agent including an MRI agent conjugated with an optical imaging agent. A method of detecting cancer is provided including injecting a dual functional contrast agent into a patient and performing both an MRI and an optical scan. The presence of the agent may indicate cancer. A method of detecting cancer by injecting PG-DTPA-Gd-NIR813 into a patient, then detecting the presence or absence of Gd in a cell or tissue of the patient and detecting the presence or absence of NIR813 in a cell or tissue of the patient is provided. The presence of Gd and NIR813 may indicate cancer.

US Patent:

20120302816, Nov 29, 2012

Filed:

Oct 27, 2010

Appl. No.:

13/504716

Inventors:

James M. Tour - Bellaire TX, US
Jacob Berlin - Monrovia CA, US
Tam Pham - Renton WA, US
Jeffrey N. Myers - Bellaire TX, US
Daisuke Sano - Yokohama, JP

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 47/18
A61K 31/711
A61K 31/7088
A61K 31/713
A61K 31/7105
A61K 31/337
A61K 31/05
A61K 39/395
A61K 31/195
A61K 9/14
A61K 47/04
A61K 47/26
A61K 47/42
A61P 35/00
A61P 31/00
A61P 39/06
A61P 29/00
A61N 5/00
A61K 38/02
B82Y 5/00
B82Y 40/00

US Classification:

600 1, 514 11, 514 44 R, 514 44 A, 514449, 514731, 4241301, 4241411, 4241381, 4241331, 514784, 514563, 424400, 514769, 514777, 514773, 977750, 977746, 977734, 977906, 977842

Abstract:

The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.

US Patent:

20150094343, Apr 2, 2015

Filed:

Jun 4, 2014

Appl. No.:

14/296267

Inventors:

- Austin TX, US
Izabela FOKT - Houston TX, US
Slawomir SZYMANSKI - Spring TX, US
Timothy MADDEN - Spring TX, US
Jeffrey MYERS - Bellaire TX, US
Charles CONRAD - Spring TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

C07D 233/64
C07C 255/44
C07D 213/57
C07C 69/732
C07C 233/29
C07D 213/64
C07D 213/61
C07C 255/41

US Classification:

514351, 514357, 514521, 514532, 514654, 514400

Abstract:

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.